Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31096231 | 1.00 | TSHR (0.56) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL7931152 | 0.90 | HPGD (0.55) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL4572874 | 0.90 | KDM4E (0.59) | TSHRHPGDSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1965362 | 0.90 | HPGD (0.51) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| Acetic Acid SCHEMBL10998868 | 0.89 | TSHR (0.53) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL4820063 | 0.88 | HPGD (0.50) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL2870711 | 0.87 | HPGD (0.50) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL7928493 | 0.87 | ALDH1A1 (0.52) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL28512540 | 0.86 | CYSLTR2 (0.51) | TSHRHPGDLMNASMN1; SMN2RAB9A | |
| SCHEMBL1847263 | 0.84 | ALDH1A1 (0.58) | TSHRHPGDLMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109796351-A | A kind of novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2019-05-24 | — | — | CN | claimed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109796351-B | Novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-109796351-B | Novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20030178607-A1 | Emissive polymers and devices incorporating these polymers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2003-09-25 | — | — | US | disclosed |
| EP-1281744-A2 | Emissive polymers and devices incorporating these polymers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20030003370-A1 | Nonaqueous electrolytic solution containing a compound which is oxidized at a voltage higher than a charge end voltage of the lithium secondary battery and a compound which inhibits reactions at voltages lower than said charge end voltage. | HITACHI, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1258939-A2 | Lithium secondary battery | Hitachi, Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-1080162-A1 | EMISSIVE POLYMERS AND DEVICES INCORPORATING THESE POLYMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| WO-1999057222-A1 | EMISSIVE POLYMERS AND DEVICES INCORPORATING THESE POLYMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-11-11 | — | — | WO | disclosed |
| US-4171361-A | HYPOTENSIVE | ELI LILLY AND COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | TSHR 3028/4885HPGD 784/4885LMNA 2076/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | TSHR 2648/4885HPGD 1240/4885LMNA 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.